MapLight reports Q3 net loss $29.4M; cash runway through 2027; Phase 2 readouts in 2026-2027

MapLight Therapeutics, Inc.

Net loss $29.4M vs $19.0M in Q3 2024; R&D spend $27.1M (up 61% YoY) on clinical trial costs.
Cash & investments $227.2M at Q3 end; Oct IPO netted $269.8M, extending runway through 2027.
Phase 2 ZEPHYR (schizophrenia, n=300) topline H2 2026; VISTA (Alzheimer's psychosis) topline H2 2027.
ML-004 (autism) IRIS Phase 2 enrollment completed (~160 pts); topline results H2 2026.
ML-021 (Parkinson's) IND-enabling studies H2 2026; ML-009 (GPR52 PAM) candidate nominated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.